Carcinogenesis is thought to originate from a single cell which accumulates a series of well-defined, albeit randomly obtained, genetic mutations, leading to carcinogenic transformation. Despite the inroads into elucidating the carcinogenesis process, there still remain gaps in our understanding of how mutations drive cell transformation and subsequent cancer progression. Although gene mutations clearly contribute to cancer, no single mutated gene or combination of mutated genes occur in all or even the majority of cancers. Moreover, as Vogelstein and Kinzler {Nature Rev Cancer 2004) point out, it is not gene mutations, but primarily chromosome-level aberrations that cells exhibit following transformation to the cancer state. Although it has long been assumed that cancers arise from mutated differentiated cells, mutated stem cells are now also considered candidate cancer precursors due to their self-renewal and differentiation capacity. Although genomic instability is ubiquitous across malignant cancers, its mechanistic underpinnings remain unclear. Inhibition of stability genes, alterations in mitosis genes, aberrant centrosomes, aneuploidy, telomere dysregulations and, for virus-linked cancers, virus-induced fusion of genetically-mutated cells, are all candidate causes of the instability. Given that gene mutations and particularly chromosome aberrations decrease the fitness of a cell, how is it that cancer cell populations are able to sustain and proliferate in the face of the high degree of chromosomal damage per cell? If the answer lies in the existence of cancer stem cells, one needs to ask how this privileged cell compartment is itself exempt from the deleterious effects of chromosomal damage.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-C)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Genesys Research Institute, Inc.
United States
Zip Code
Radivoyevitch, Tomas; Jankovic, Gradimir M; Tiu, Ramon V et al. (2014) Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys 53:55-63
Weekes, Suzanne L; Barker, Brian; Bober, Sarah et al. (2014) A multicompartment mathematical model of cancer stem cell-driven tumor growth dynamics. Bull Math Biol 76:1762-82
Nguyen, David H; Ouyang, Haoxu; Mao, Jian-Hua et al. (2014) Distinct luminal-type mammary carcinomas arise from orthotopic Trp53-null mammary transplantation of juvenile versus adult mice. Cancer Res 74:7149-58
Benzekry, S├ębastien; Lamont, Clare; Beheshti, Afshin et al. (2014) Classical mathematical models for description and prediction of experimental tumor growth. PLoS Comput Biol 10:e1003800
Benzekry, S├ębastien; Gandolfi, Alberto; Hahnfeldt, Philip (2014) Global dormancy of metastases due to systemic inhibition of angiogenesis. PLoS One 9:e84249
Beheshti, Afshin; Peluso, Michael; Lamont, Clare et al. (2014) Proton irradiation augments the suppression of tumor progression observed with advanced age. Radiat Res 181:272-83
Gale, Robert Peter; Hlatky, Lynn; Sachs, Rainer K et al. (2014) Why is there so much therapy-related AML and MDS and so little therapy-related CML? Leuk Res 38:1162-4
Poleszczuk, J; Hahnfeldt, P; Enderling, H (2014) Biphasic modulation of cancer stem cell-driven solid tumour dynamics in response to reactivated replicative senescence. Cell Prolif 47:267-76
Prochazka, Vaclav; Klosova, Hana; Stetinsky, Jiri et al. (2014) Addition of platelet concentrate to dermo-epidermal skin graft in deep burn trauma reduces scarring and need for revision surgeries. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158:242-58
Hlatky, Lynn; Hahnfeldt, Philip (2014) Beyond the cancer cell: progression-level determinants highlight the multiscale nature of carcinogenesis risk. Cancer Res 74:659-64

Showing the most recent 10 out of 27 publications